B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
IBRX
ImmunityBioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q1 preliminary revenue growth, expanding ANKTIVA geographic reach, and a fully enrolled QUILT-2.005 study support a real commercial-plus-regulatory path if the upcoming 10-Q validates the preliminary figures and 2026 regulatory milestones stay on track [#8-K-2026-04-09].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.2.
What can break
Formal Q1 2026 results could disappoint versus the April 9 preliminary figures.
Momentum
92
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.50Analysis 2026-04-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $14.25
Why
Momentum92 · Δ7d -3.2
Value41 · Δ7d -0.1
Sentiment46 · Δ7d +6.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.2.
Contradictions & invalidation
- • Formal Q1 2026 results could disappoint versus the April 9 preliminary figures.
- • Going-concern and capital-raising risk remains material if commercial growth slows.
- • The 10-K says substantial doubt exists about the company’s ability to continue as a going concern without additional funding, and the March financing amendment improved liquidity at the cost of a larger future revenue share, so execution misses or slower ANKTIVA uptake could compress the equity quickly [#10-K-2026-02-23] [#8-K-2026-03-30].
Catalyst clock
2026-05-15
Q1 2026 10-Q needs to reconcile preliminary revenue and liquidity figures
Lead driver: Sentiment · See AI snapshot
Momentum
92
8% active weight
Current posture
7d trendImproving
Δ7d
-3.2
Δ21d
-2.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
46
45% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+20.4
Why this grade
Composite grade D. Momentum 92.2 / Value 40.6 / Sentiment 45.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$9.15B
Beta
-0.02
Shares Out
1.06B
P/E (TTM) · Derived
-22.6
P/S (TTM)
24.82
P/FCF (TTM) · Derived
-30.03
Rev YoY
+93.9%
EPS YoY
+110.6%
Gross Margin
+89.3%
Op Margin
-151.9%
Net Debt
$601.85M
Current Ratio
5.72
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data